Inactive Instrument

Highlights Kadimastem Ltd TEL AVIV STOCK EXCHANGE

Equities

Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	Feb. 28	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	Feb. 27	CI
Kadimastem Plans Listing on Nasdaq Through Merger	Feb. 18	CI
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	Nov. 07	CI
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Kadimastem to Launch Clinical Trial in ALS Patients Upon Approval from the Hadassah Hospital IRB	17-06-22	CI
Kadimastem Receives Approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the Phase 1/2A Clinical Trial in Als Patients	17-06-21	CI
Kadimastem Announces Granting a Patent in the US for Treatment of Neurodegenerative Diseases	17-03-16	CI

No results for this search